Targeting the Skeletal Muscle to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: High-intensity interval training, Moderate intensity exercise training, Low intensity exercise training.
- Who it may be relevant to
- Registry conditions: Metabolic Dysfunction-associated Steatotic Liver Disease. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Belgium
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Targeting Myosteatosis Though Physical Exercise to Treat Metabolic Dysfunction-associated Steatotic Liver Disease
Overview
Muscle changes including myosteatosis are reported as highly prevalent in metabolic dysfunction-associated steatotic liver disease (MASLD). Recent studies highlighted a link between muscle fat content and liver disease severity. Conversely, MASLD histological remission though diet or metabolic surgeries is also linked to a decrease in muscle fat content. Therefore, skeletal muscle appears as a potential target to treat MASLD.
Detailed description
In this monocenter interventional study, we will assess the impact of physical activity on muscle fat content and liver disease severity in MASLD as well as the mechanisms mediating the potential beneficial effects of exercise.
Interventions
- Other High-intensity interval training
High-intensity interval training - Other Moderate intensity exercise training
Moderate intensity exercise training - Other Low intensity exercise training
Low intensity exercise training
Primary outcome measures
- the impact of physical activity on muscle and liver phenotypes [Time frame: every four weeks from baseline till study completion]
Eligibility criteria
Inclusion criteria
- confirmed MASLD at abdominal imaging
- confirmed excessive muscle lipid content at imaging
- stable weight
Exclusion criteria
- severe comorbidities including active malignancies, neuromuscular degenerative diseases
- contraindications to physical activity
- excessive alcohol consumption
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Belgium · 2 centers
- Cliniques universitaires Saint-Luc — Brussels
- Centre d'investigation clinique en nutrition — Louvain-la-Neuve
Publications
- Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep. 2023 Nov 14;6(2):100963. doi: 10.1016/j.jhepr.2023.100963. eCollection 2024 Feb. PMID 38322420
- Henin G, Loumaye A, Deldicque L, Leclercq IA, Lanthier N. Unlocking liver health: Can tackling myosteatosis spark remission in metabolic dysfunction-associated steatotic liver disease? Liver Int. 2024 Aug;44(8):1781-1796. doi: 10.1111/liv.15938. Epub 2024 Apr 16. PMID 38623714
Identifiers
NCT: NCT06506513 · ST-IR-01 MYO-MASLD